Abstract
A series of chromone derivatives were designed as potential topoisomerase I (Top I) inhibitors based on the docking simulation study. Sixteen synthesized compounds were evaluated for Top I inhibitory activity and some compounds were further tested for in vitro cytotoxic activity. The most potent inhibitor, chromone 11b showed greater inhibitory activity (IC50 = 1.46 μM) than the known Top I inhibitors, i.e., camptothecin, fisetin and morin, but inactive against breast cancer cell (MCF-7), oral cavity cancer cell (KB) and small cell lung cancer (NCI-H187). Chromone 11c, another potent inhibitor (IC50 = 6.16 μM), exhibited cytotoxic activity against KB (IC50 = 73.32 μM) and NCI-H187 (IC50 = 36.79 μM).
Keywords: Chromone derivatives, topoisomerase I inhibitory activity, cytotoxic activity, enzymes, DNA, flavonoids, hydrogen bonds, melting points, dimethylsulfoxide, chromatography
Medicinal Chemistry
Title:Synthesis, Topoisomerase I Inhibitory and Cytotoxic Activities of Chromone Derivatives
Volume: 9 Issue: 3
Author(s): Chirattikan Maicheen, Jiraphun Jittikoon, Opa Vajragupta and Jiraporn Ungwitayatorn
Affiliation:
Keywords: Chromone derivatives, topoisomerase I inhibitory activity, cytotoxic activity, enzymes, DNA, flavonoids, hydrogen bonds, melting points, dimethylsulfoxide, chromatography
Abstract: A series of chromone derivatives were designed as potential topoisomerase I (Top I) inhibitors based on the docking simulation study. Sixteen synthesized compounds were evaluated for Top I inhibitory activity and some compounds were further tested for in vitro cytotoxic activity. The most potent inhibitor, chromone 11b showed greater inhibitory activity (IC50 = 1.46 μM) than the known Top I inhibitors, i.e., camptothecin, fisetin and morin, but inactive against breast cancer cell (MCF-7), oral cavity cancer cell (KB) and small cell lung cancer (NCI-H187). Chromone 11c, another potent inhibitor (IC50 = 6.16 μM), exhibited cytotoxic activity against KB (IC50 = 73.32 μM) and NCI-H187 (IC50 = 36.79 μM).
Export Options
About this article
Cite this article as:
Maicheen Chirattikan, Jittikoon Jiraphun, Vajragupta Opa and Ungwitayatorn Jiraporn, Synthesis, Topoisomerase I Inhibitory and Cytotoxic Activities of Chromone Derivatives, Medicinal Chemistry 2013; 9 (3) . https://dx.doi.org/10.2174/1573406411309030003
DOI https://dx.doi.org/10.2174/1573406411309030003 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Isolation of Chlorogenic Acid from Soil Borne Fungi Screlotium rolfsii, their Reversal of Multidrug Resistance and Anti-proliferative in Mouse Lymphoma Cells
Medicinal Chemistry The Role of Phenolic Compounds in the Fight against Cancer – A Review
Anti-Cancer Agents in Medicinal Chemistry Pioglitazone Prevents Smoking Carcinogen-Induced Lung Tumor Development in Mice
Current Cancer Drug Targets Generation of Bispecific Antibodies by Fc Heterodimerization and their Application
Current Pharmaceutical Biotechnology Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies
Current Clinical Pharmacology Effects of Nanosuspension Formulations on Transport, Pharmacokinetics, In Vivo Targeting and Efficacy for Poorly Water-soluble Drugs
Current Pharmaceutical Design Recent Advances in Therapeutic Peptides for Breast Cancer Treatment
Current Protein & Peptide Science Synthesis, Radiosynthesis and Metabolism of 131I-Y-c(CGRRAGGSC)
Anti-Cancer Agents in Medicinal Chemistry Modulation of TRAIL-Induced Apoptosis by HDAC Inhibitors
Current Cancer Drug Targets Targeting Heparan Sulfate Proteoglycans in Breast Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Hydrogel-clay Nanocomposites as Carriers for Controlled Release
Current Medicinal Chemistry The True Face of the Revolution in Oncology Drug Development: A Personal Reflection
Current Clinical Pharmacology Can Untargeted Metabolomics Be Utilized in Drug Discovery/Development?
Current Topics in Medicinal Chemistry A Role for the Inflammatory Mediators Cox-2 and Metalloproteinases in Cancer Stemness
Anti-Cancer Agents in Medicinal Chemistry The Role of Foxp3 in Regulatory T Cell Differentiation and Function
Current Immunology Reviews (Discontinued) Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules
Current Medicinal Chemistry Editorial (Thematic Issue : Frontier View on Drug Discoveries for Different Diseases - Part I )
Current Drug Metabolism Targeting Plasminogen Activator Inhibitor-1: Role in Cell Signaling and the Biology of Domain-Specific Knock-in Mice
Current Drug Targets PET Radioligands for In Vivo Visualization of Neuroinflammation
Current Pharmaceutical Design Recent Advances in Treatment of Lung Cancer: Nanoparticle-based Drug and siRNA Delivery Systems
Current Drug Delivery